- Home
- ADPT vs VKTX Comparison
ADPT vs VKTX Comparison
Compare ADPT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADPT | VKTX |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.0B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADPT | VKTX |
|---|---|---|
| Price | $28.14 | $26.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | $30.21 | ★ $95.32 |
| AVG Volume (30 Days) | 2.0M | ★ 4.8M |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $22.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $12.00 | $23.82 |
| 52 Week High | $30.74 | $43.15 |
Technical Indicators
Market Signals| Indicator | ADPT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 46.14 |
| Support Level | $23.73 | $26.47 |
| Resistance Level | $30.35 | $34.00 |
| Average True Range (ATR) | 1.47 | 1.49 |
| MACD | 0.32 | 0.14 |
| Stochastic Oscillator | 83.27 | 59.36 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.